CYDY News and Press, CytoDyn Inc From 11/24/21

The 60 double-blinded arm (700 mg) will be unblinded by early December CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic...

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that its research paper entitled “CCR5 recepto...

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Health Canada authorized the emergency use of le...

Management Team Will Present on Company’s Strategy Going Forward VANCOUVER, Washington, Nov. 16, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 an...

CytoDyn (OTCQB:CYDY) has initiated the resubmission of its Biologics License Application (BLA) for HIV under rolling review consistent with guidance from the FDA. The resubmission will include non-clinical and CMC sections during November, followed by submission of the clinical section in Q1 ...

Second portion out of three major portions of BLA (CMC portion) will be submitted shortly Clinical section (last portion to complete BLA) expected to be submitted during Q1 2022 VANCOUVER, Washington, Nov. 16, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“Cy...

Rivalry with Pfizer starting to take shape. First market mover advantage is a stop-gap measure. Ideal partnership combination with Todos Medical. For further details see: Merck's Plan B Percolates After Pfizer Announces Dominance

CytoDyn (OTCQB:CYDY) has submitted to the U.S. FDA an application for Breakthrough Therapy designation for leronlimab as a potential treatment for Metastatic Triple-Negative Breast Cancer ((mTNBC)). Previously, the FDA had granted CytoDyn Fast Track designation to explore two potent...

Ongoing analysis of data from 28 mTNBC patients following 12 months of treatment with leronlimab is very encouraging given little-to- no effective treatment options currently VANCOUVER, Washington, Nov. 08, 2021 (GLOBE NEWSWIRE) -- ...

CytoDyn recently reported preliminary analysis from Leronlimab in mTNBC patients and NASH. I believe this data supports further development of Leronlimab in NASH and cancer indications. The recent data has provided me enough confidence to change my strategy. I am looking to start allo...